Abstract
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have